Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma

Published:2022-09 Issue:6 Volume:22 Page:741-748
ISSN:1424-3903
Container-title:Pancreatology
language:en
Short-container-title:Pancreatology

Author:

Ueberroth Benjamin E.^ORCID,Jones Jeremy C.,Bekaii-Saab Tanios S.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Endocrinology, Diabetes and Metabolism

Reference53 articles.

1. Recurrence after resection for ductal adenocarcinoma of the pancreas;Sperti;World J Surg,1997

2. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a seer-based study;Saad;BMC Cancer,2018

3. 8th edition of the ajcc cancer staging manual: pancreas and hepatobiliary cancers;Chun;Ann Surg Oncol,2018

4. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer;Axelrod;Clin Cancer Res,2020

5. Detection of minimal residual disease using ctdna in lung cancer: current evidence and future directions;Chae;J Thorac Oncol,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience;Annals of Surgical Oncology;2024-07-02

2. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol;BMJ Open;2024-07

3. Postoperative tumor treatment strategies: From basic research to clinical therapy;VIEW;2024-05-29

4. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study;Annals of Surgical Oncology;2024-01-03

5. The role of matrix metalloproteinase-2 in the metastatic cascade: a review;Oncologie;2024-01-01